The National Institutes of Health (NIH) has granted a Phase II Fast Track small business technology transfer (STTR) grant to Materia to develop functional polymers for use in organic synthesis.
The focus of the new Phase II programme will be on polymer process development, scale up and beta testing, with the help of industrial partners.
Michael Giardello, Materia chief executive officer, said: "These materials provide higher functional group content, reduced swelling and enhanced solvent compatibility versus state-of-the-art polystyrene-bound reagents, and their commercialisation may ultimately expedite the timeframe at which new therapeutic agents become available to consumers."
The Phase II programme is a continuation of the combined effort between Materia and the University of Kansas. University of Kansas professor Paul Hanson said the university is excited and honoured to be continuing its collaboration with Materia, which will enable further development of a new and challenging science.
"Materia's expertise in polymerisation, scale up and commercialisation will drive efforts moving forward," Hanson added.
Materia develops a green chemical olefin metathesis catalyst technology for chemical, polymer and pharmaceutical industries, enabling chemical compounds to be synthesised with higher efficiency, as well as less harmful waste and fewer by-products.